摘要
目的系统评价阴道用乳酸菌制剂辅助治疗复发性外阴阴道假丝酵母菌病(RVVC)的疗效及安全性。方法计算机检索CNKI、万方、维普、PubMed及Cochrane等数据库(检索时间为各数据库创建时间至2018年1月),纳入关于阴道用乳酸菌制剂辅助治疗RVVC的临床随机对照试验(RCT),采用RevMan 5.3软件对相关研究进行Meta分析。结果共纳入32篇RCT,包括3 635例患者,结果显示:阴道用乳酸菌制剂辅助治疗RVVC的痊愈率优于单纯抗菌药物[P<0.001,OR=2.15,95%CI(1.81,2.54)],总有效率高[P<0.001,OR=3.26,95%CI (2.5,4.26)],复发率低[P<0.001,OR=0.19,95%CI (0.15,0.25)],不良反应发生率低,Begg′s检验表明纳入的RCT研究无发表偏倚(P=0.102>0.05)。结论基于现有临床证据,阴道用乳酸菌制剂辅助治疗RVVC疗效优于单纯抗菌药物,可有效改善临床症状,减少疾病发作次数,安全性高,不良反应发生率低,值得临床推广使用。
Objective To evaluate efficacy and safety of adjuvant therapy of recurrent vulvovaginal candidiasis (RVVC)with lactobacillus preparation versus antifungal agents alone.Methods CNKI,Wanfang data, VIP,PubMed and Cochrane library were searched for RCTs about adjuvant treatment of RVVC with vaginal lactobacillus preparation,and the meta-analysis was conducted by using RevMan 5.3software.Results Thirty-two studies were included and 3,635patients were involved.The results showed that the efficacy of vaginal lactobacillus preparation as the auxiliary treatment of RVVC was superior to that of antifungal agents alone.The ORs of cure rate and the efficiency rate were 2.15(95%CI:1.81-2.54)and 3.26(95%CI:2.5-4.26) respectively.The recurrence rate was low with an OR=0.19(95%CI:0.15-0.25)and publication bias of these RCTs was not significant.Conclusion Adjuvant therapy of RVVC with vaginal Iactobacillus preparation is more effective than antifuhgal agents alone,with lower recurrence rate and less adverse reactions.
作者
郭淑敏
周秀丽
朱玲
GUO Shumin;ZHOU Xiuli;ZHU Ling(Guangzhou Universzty of Chinese Medzcine,Guangzhou,Guangdong 510405,China)
出处
《中国微生态学杂志》
CAS
CSCD
2018年第11期1317-1325,共9页
Chinese Journal of Microecology
基金
广东省教育厅科研项目(2014KZDXM024)
